These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

302 related items for PubMed ID: 5406970

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [Parkinson's syndrome. 4 years of experience in treatment with L Dopa associated with a decarboxylase inhibitor. Clinical and biochemical study].
    Tissot R, de Ajuriaguerra J.
    Nouv Presse Med; 1973 Feb 03; 2(5):315-6. PubMed ID: 4686226
    [No Abstract] [Full Text] [Related]

  • 4. [Therapy of Parkinson's syndrome with L-dopa and a decarboxylase inhibitor (Ro 4-4602). Course in 71 patients].
    Ferel D.
    Schweiz Med Wochenschr; 1972 Jan 22; 102(3):88-94. PubMed ID: 4551909
    [No Abstract] [Full Text] [Related]

  • 5. [Potentiation of L-Dopa in parkinsonism by means of an inhibitor of peripheral decarboxylation].
    Court J, Kase JC, Mena I, Palacios E.
    Rev Med Chil; 1973 Jun 22; 101(6):452-5. PubMed ID: 4764560
    [No Abstract] [Full Text] [Related]

  • 6. [Experiences in the treatment of Parkinson's disease with a combination drug: L-dopa plus decarboxylase inhibitor (Ro 8-0576)].
    Steinhäusl H.
    Wien Med Wochenschr; 1973 Jun 30; 123(26):433-5. PubMed ID: 4578743
    [No Abstract] [Full Text] [Related]

  • 7. [Treatment of Parkinson's disease with L-dopa combined with a decarboxylase inhibitor].
    Siegfried J, Klaiber R, Perret E, Ziegler WH.
    Dtsch Med Wochenschr; 1969 Dec 26; 94(52):2678-81. PubMed ID: 4903342
    [No Abstract] [Full Text] [Related]

  • 8. [Disturbances of catecholamine metabolism (with special reference to dopamine) in the Parkinsonian syndrome].
    Tissot R.
    Presse Med (1893); 1969 Apr 05; 77(17):617-8. PubMed ID: 5785080
    [No Abstract] [Full Text] [Related]

  • 9. Levodopa combined with MK 486 (L-alpha methyldopahydrazine)--a peripheral decarboxylase inhibitor in Parkinson's disease.
    Andrews CJ, Somerville B.
    Med J Aust; 1974 Mar 23; 1(12):429-32. PubMed ID: 4598384
    [No Abstract] [Full Text] [Related]

  • 10. Levodopa combined with peripheral decarboxylase inhibition in Parkinson's disease.
    Barbeau A, Mars H, Botez MI, Joubert M.
    Can Med Assoc J; 1972 Jun 10; 106(11):1169-74. PubMed ID: 5034697
    [Abstract] [Full Text] [Related]

  • 11. [Drug therapy of Parkinson's syndrome. Clinical long-term study using L-dopa and the drug conbination L-dopa-decarboxylase inhibitor].
    Christiani K, Möller WD.
    Munch Med Wochenschr; 1973 Apr 20; 115(16):711-3. PubMed ID: 4197759
    [No Abstract] [Full Text] [Related]

  • 12. [L-dopa therapy of Parkinson's syndrome. Comparison of pure L-dopa and the combination preparation L-dopa and decarboxylase inhibitor].
    Görlich J, Markus E.
    Dtsch Med Wochenschr; 1972 Aug 25; 97(34):1246-8. PubMed ID: 5048316
    [No Abstract] [Full Text] [Related]

  • 13. [Treatment of Parkinson's syndrome with L-dopa and its methylated derivatives: 3-OMD and 4-OMD associated with a decarboxylase inhibitor. Clinical and biochemical study].
    Tissot R, Bartholini G, Constantinidis J, Eisenring JJ, Geissbühler F, Yanniotis G, de Ajuriaguerra J.
    Schweiz Med Wochenschr; 1973 Oct 20; 103(42):1466-74. PubMed ID: 4750149
    [No Abstract] [Full Text] [Related]

  • 14. [Treatment of Parkinson's syndrome with L-dopa and a decarboxylase inhibitor].
    Lombardo L, de la Garza R, Ivan-Reynoso G.
    Arch Invest Med (Mex); 1974 Oct 20; 5(2):105-16. PubMed ID: 4433198
    [No Abstract] [Full Text] [Related]

  • 15. [Quantitative rigor determination in Parkinson's disease. Myo-integration for therapy control of L-Dopa in combination with a decarboxylase inhibitor (Ro 8-0576)].
    Gehlen W, Eisenlohr JJ.
    Nervenarzt; 1974 Jan 20; 45(2):22-9. PubMed ID: 4601993
    [No Abstract] [Full Text] [Related]

  • 16. [Advantages of the combination therapy (L-Dopa and decarboxylase inhibitors) in parkinsonism].
    Gattringer B, Steinhäusl H.
    Wien Med Wochenschr; 1972 Jun 17; 122(25):369-71. PubMed ID: 4558132
    [No Abstract] [Full Text] [Related]

  • 17. [Treatment of Parkinsonism with oral L-DOPA combined with a decarboxylase inhibitor (Ro IV 46.02)].
    Tissot R, Gaillard JM, Guggisberg M, Gauthier G, de Ajuriaguerra J.
    Presse Med (1893); 1969 Apr 05; 77(17):619-22. PubMed ID: 5785081
    [No Abstract] [Full Text] [Related]

  • 18. L-Dopa, B 6 , and alpha-methyldopa hydrazine.
    Klawans HL, Ringel SP.
    Confin Neurol; 1973 Apr 05; 35(3):186-92. PubMed ID: 4712885
    [No Abstract] [Full Text] [Related]

  • 19. [2-year experiences with a combination treatment of Parkinsonism with L-dopa and a decarboxylase inhibitor (Benserazid, Ro 4-4602)].
    Birkmayer W, Linauer W, Mentasti M, Riederer P.
    Wien Med Wochenschr; 1974 Jun 01; 124(22):340-4. PubMed ID: 4275492
    [No Abstract] [Full Text] [Related]

  • 20. [Therapy of Parkinsonism using L-dopa in combination with a decarboxylase inhibitor].
    Stammler A, Vielhaber K.
    Fortschr Neurol Psychiatr Grenzgeb; 1972 Oct 01; 40(10):564-8. PubMed ID: 4565521
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.